Xeris Biopharma Holdings, Inc. (XERS)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Xeris Biopharma Holdings, Inc. reported revenue of $291.85M, up 43.7% from the prior year. The company was profitable, with a net margin of 0.2%. It held $383.53M in total assets against $369.84M in total liabilities.
Key ratios (FY2025)
8.5%
Operating margin
0.2%
Net margin
4.0%
Return on equity
+43.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M | $20.16M | — |
| Operating Income | $24.90M | -$33.65M | -$44.01M | -$81.94M | -$115.16M | -$83.55M | — |
| Net Income | $554.0K | -$54.84M | -$62.26M | -$94.66M | -$122.72M | -$91.14M | — |
| EPS (Diluted) | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | — | — |
| Total Assets | $383.53M | $323.06M | $322.60M | $344.52M | $304.36M | $159.15M | — |
| Total Liabilities | $369.84M | $352.68M | $329.38M | $299.33M | $209.13M | $125.39M | — |
| Shareholders' Equity | $13.69M | -$29.61M | -$6.78M | $45.19M | $95.23M | $33.76M | $14.44M |
| Cash & Equivalents | $111.04M | $71.62M | $67.45M | $121.97M | $67.27M | $37.60M | $19.52M |
| Operating Cash Flow | $28.63M | -$36.98M | -$47.02M | -$102.89M | -$95.53M | -$80.56M | — |
| Capital Expenditures | — | — | — | — | $1.08M | $377.0K | — |
| Shares Outstanding | 166.22M | 149.43M | 138.13M | 136.27M | 124.87M | — | — |